Marksans Pharma Limited has notified stock exchanges of a scheduled Q4FY26 Earnings Conference Call for analysts and investors on Wednesday, May 27, 2026 at 04:30 PM IST. The announcement was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call will cover the audited financial results — both Standalone and Consolidated — for the quarter and year ended March 31, 2026.

Conference Call Details

The earnings call will feature senior members of Marksans Pharma's management team and will be facilitated by DAM Capital Advisors Ltd. The following key details summarise the event:

Management Speakers

The following members of Marksans Pharma's leadership will address the call:

• Mr. Mark Saldanha – Founder, Chairman and Managing Director
• Mr. Jitendra Sharma – Chief Financial Officer

Dial-In Information

Participants can join the call using the following access numbers. The company advises dialling in at least 5–10 minutes prior to the scheduled start time.

Universal Access (all networks and countries):

• +91 22 6280 1384
• +91 22 7115 8285

International Dial-In Numbers:

For further information, participants may contact Nitin Agarwal or Payal Shah at DAM Capital Advisors Limited via phone at +91 22 4202 2568 / 2638 or by email at nitin.a@damcapital.in / payal@damcapital.in .

Post-Call Resources

Following the conference call, the presentation, audio recording, and transcript will be hosted on the company's official website at https://www.marksanspharma.com/earnings-call-transcripts.html . The intimation letter was signed by Harshavardhan Panigrahi, Company Secretary, on May 19, 2026.

Marksans Pharma has notified the stock exchanges of an upcoming board meeting scheduled for Tuesday, May 26, 2026, at Mumbai. The intimation has been filed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will address key financial and corporate matters pertaining to the concluded fiscal year.

Key Agenda Items

The board meeting has been convened to transact the following businesses, as detailed in the regulatory filing:

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Internal Code on Prohibition of Insider Trading, the trading window for dealing in the company's shares has been closed for Designated Persons, including Directors, and their immediate relatives. The key details of the trading window restriction are as follows:

• Closure Date: April 01, 2026
• Re-opening Date: Forty-eight hours after the announcement of financial results, i.e., up to May 28, 2026 (both days inclusive)

Regulatory Compliance and Disclosure

As required under the Listing Regulations, the board meeting intimation is available on the company's official website at www.marksanspharma.com , as well as on the websites of BSE Limited and the National Stock Exchange of India Limited. The filing was signed by Harshavardhan Panigrahi, Company Secretary, on May 12, 2026. The company is headquartered at the 11th Floor, "GRANDEUR", Oshiwara, Andheri (W), Mumbai – 400 053.